Impax Laboratories Company Profile (NASDAQ:IPXL)

About Impax Laboratories

Impax Laboratories logoImpax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: IPXL
  • CUSIP: 45256B10
Key Metrics:
  • Previous Close: $21.45
  • 50 Day Moving Average: $23.98
  • 200 Day Moving Average: $28.65
  • 52-Week Range: $20.97 - $45.00
  • Trailing P/E Ratio: 45.44
  • Foreward P/E Ratio: 9.25
  • P/E Growth: 0.61
  • Market Cap: $1.53B
  • Outstanding Shares: 71,232,000
  • Beta: 1.21
  • Net Margins: 3.78%
  • Return on Equity: 11.30%
  • Return on Assets: 6.25%
  • Debt-to-Equity Ratio: 0.41%
  • Current Ratio: 2.92%
  • Quick Ratio: 2.36%
Additional Links:
Companies Related to Impax Laboratories:

Analyst Ratings

Consensus Ratings for Impax Laboratories (NASDAQ:IPXL) (?)
Ratings Breakdown: 10 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $33.38 (55.64% upside)

Analysts' Ratings History for Impax Laboratories (NASDAQ:IPXL)
DateFirmActionRatingPrice TargetDetails
9/27/2016Goldman Sachs Group Inc.UpgradeSell -> Neutral$25.00 -> $26.00View Rating Details
8/15/2016Northland SecuritiesUpgradeMarket Perform -> Outperform$30.00View Rating Details
8/13/2016Piper Jaffray Cos.Reiterated RatingOverweight$40.00 -> $32.00View Rating Details
8/11/2016RBC Capital MarketsReiterated RatingSector Perform$35.00 -> $30.00View Rating Details
8/10/2016Deutsche Bank AGLower Price TargetHold$31.00 -> $24.00View Rating Details
8/10/2016Leerink SwannLower Price TargetMarket Perform$33.00 -> $24.00View Rating Details
8/10/2016WallachBeth CapitalLower Price TargetBuy$40.00 -> $30.00View Rating Details
8/10/2016Royal Bank Of CanadaLower Price TargetSector Perform$35.00 -> $30.00View Rating Details
6/28/2016BMO Capital MarketsInitiated CoverageMarket Perform$30.00View Rating Details
6/21/2016Bank of America Corp.UpgradeUnderperform -> NeutralView Rating Details
6/1/2016JPMorgan Chase & Co.Initiated CoverageNeutral$47.00View Rating Details
4/15/2016BTIG ResearchReiterated RatingBuy$48.00View Rating Details
3/2/2016NomuraReiterated RatingHoldView Rating Details
2/23/2016SusquehannaLower Price TargetPositive$55.00 -> $43.00View Rating Details
2/17/2016Raymond James Financial Inc.UpgradeUnderperform -> Market PerformView Rating Details
9/8/2015GuggenheimReiterated RatingBuy$53.50 -> $60.00View Rating Details
4/6/2015JMP SecuritiesBoost Price TargetMarket Outperform$48.00 -> $56.00View Rating Details
2/25/2015Needham & Company LLCBoost Price TargetBuy$37.00 -> $46.00View Rating Details
(Data available from 10/27/2014 forward)


Earnings History for Impax Laboratories (NASDAQ:IPXL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216$0.32$0.21$223.67 million$173.00 millionViewN/AView Earnings Details
5/10/2016Q116$0.39$0.43$241.84 million$226.00 millionViewListenView Earnings Details
2/22/2016Q415$0.44$0.62$223.23 million$282.10 millionViewListenView Earnings Details
11/9/2015Q315$0.39$0.40$214.69 million$221.10 millionViewN/AView Earnings Details
8/10/2015Q215$0.35$0.34$200.68 million$214.20 millionViewListenView Earnings Details
5/11/2015Q115$0.18$0.09$146.00 million$143.10 millionViewListenView Earnings Details
2/24/2015Q414$0.12$0.16$125.50 million$131.20 millionViewN/AView Earnings Details
11/4/2014Q314$0.31$0.33$148.36 million$145.63 millionViewN/AView Earnings Details
8/6/2014Q214$0.36$0.60$155.97 million$188.10 millionViewN/AView Earnings Details
5/1/2014Q114$0.05$0.24$97.80 million$118.70 millionViewN/AView Earnings Details
2/20/2014Q413$0.03($0.14)$119.01 million$100.74 millionViewN/AView Earnings Details
11/4/2013Q313($0.08)$0.25$111.83 million$115.75 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.04$0.08$120.75 million$129.63 millionViewN/AView Earnings Details
5/1/2013Q1 2013$0.21$0.37$129.12 million$148.50 millionViewN/AView Earnings Details
2/25/2013Q4 2012$0.19$0.30$127.03 million$141.10 millionViewN/AView Earnings Details
10/30/2012Q312$0.49$0.48$160.76 million$145.60 millionViewN/AView Earnings Details
7/31/2012$0.44$0.60ViewN/AView Earnings Details
5/1/2012$0.45$0.52ViewN/AView Earnings Details
2/28/2012$0.19$0.33ViewN/AView Earnings Details
11/1/2011$0.20$0.30ViewN/AView Earnings Details
8/2/2011$0.18$0.19ViewN/AView Earnings Details
5/3/2011$0.15$0.21ViewN/AView Earnings Details
2/24/2011$0.22$0.23ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Impax Laboratories (NASDAQ:IPXL)
Current Year EPS Consensus Estimate: $1.59 EPS
Next Year EPS Consensus Estimate: $2.32 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.39$0.51$0.45
Q2 20161$0.33$0.33$0.33
Q3 20161$0.38$0.38$0.38
Q4 20161$0.54$0.54$0.54
(Data provided by Zacks Investment Research)


Dividend History for Impax Laboratories (NASDAQ:IPXL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Impax Laboratories (NASDAQ:IPXL)
Insider Ownership Percentage: 3.30%
Institutional Ownership Percentage: 88.13%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2016Leslie Z BenetDirectorSell10,092$22.81$230,198.52View SEC Filing  
9/11/2015Mark A SchlossbergSVPSell7,457$43.30$322,888.10View SEC Filing  
9/10/2015Michael NestorInsiderSell5,000$43.56$217,800.00View SEC Filing  
8/31/2015Michael MarkbreiterDirectorSell28,000$41.70$1,167,600.00View SEC Filing  
8/27/2015Mark A SchlossbergSVPSell4,649$43.41$201,813.09View SEC Filing  
8/27/2015Peter R TerreriDirectorSell4,833$43.93$212,313.69View SEC Filing  
8/26/2015Michael MarkbreiterDirectorSell19,399$42.24$819,413.76View SEC Filing  
6/6/2014Larry HsuDirectorSell100,000$28.38$2,838,000.00View SEC Filing  
5/27/2014Peter R TerreriDirectorSell3,000$28.00$84,000.00View SEC Filing  
5/22/2014Larry HsuDirectorSell50,000$27.22$1,361,000.00View SEC Filing  
5/21/2014Larry HsuDirectorSell3,800$26.53$100,814.00View SEC Filing  
5/16/2014Nigel FlemingDirectorSell1,900$25.72$48,868.00View SEC Filing  
5/12/2014Nigel FlemingDirectorSell1,333$26.58$35,431.14View SEC Filing  
5/8/2014Michael MarkbreiterDirectorSell12,500$26.44$330,500.00View SEC Filing  
5/6/2014Larry HsuDirectorSell219,386$26.28$5,765,464.08View SEC Filing  
3/11/2014Michael MarkbreiterDirectorSell4,000$27.54$110,160.00View SEC Filing  
1/8/2014Robert BurrDirectorSell1,500$24.31$36,465.00View SEC Filing  
11/13/2013Robert BurrDirectorSell1,500$22.98$34,470.00View SEC Filing  
10/9/2013Robert BurrDirectorSell1,500$20.10$30,150.00View SEC Filing  
9/11/2013Robert BurrDirectorSell1,500$20.87$31,305.00View SEC Filing  
8/14/2013Robert BurrDirectorSell1,500$21.15$31,725.00View SEC Filing  
7/10/2013Robert L BurrDirectorSell1,500$20.26$30,390.00View SEC Filing  
6/12/2013Robert L BurrDirectorSell1,500$18.80$28,200.00View SEC Filing  
5/8/2013Robert L BurrDirectorSell1,500$16.35$24,525.00View SEC Filing  
5/1/2013Peter R TerreriDirectorSell3,450$17.39$59,995.50View SEC Filing  
3/12/2013Larry HsuCEOBuy7,000$16.88$118,160.00View SEC Filing  
3/12/2013Mark A SchlossbergSVPBuy1,000$16.73$16,730.00View SEC Filing  
2/13/2013Robert L BurrDirectorSell1,500$19.82$29,730.00View SEC Filing  
11/14/2012Robert L BurrDirectorSell1,500$19.86$29,790.00View SEC Filing  
8/20/2012Nigel FlemingDirectorSell6,000$23.99$143,940.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Impax Laboratories (NASDAQ:IPXL)
DateHeadline logoETF’s with exposure to Impax Laboratories, Inc. : October 20, 2016 (NASDAQ:IPXL) - October 20 at 5:54 PM logoImpax Laboratories, Inc. (NASDAQ:IPXL) Is Expected To Post EPS Of $0.58 (NASDAQ:IPXL) - October 15 at 10:24 AM logoImpax Laboratories Enters Oversold Territory (IPXL) (NASDAQ:IPXL) - October 15 at 10:24 AM logoETF’s with exposure to Impax Laboratories, Inc. : October 6, 2016 (NASDAQ:IPXL) - October 6 at 11:04 AM logoImpax to Report Third Quarter 2016 Results on November 9, 2016 (NASDAQ:IPXL) - October 4 at 10:27 AM
News IconGoldman Sachs Gives Impax Laboratories, Inc. Price Target With Potential 2.36% Upside (NASDAQ:IPXL) - September 28 at 5:29 PM logoImpax Laboratories, Inc. – Value Analysis (NASDAQ:IPXL) : September 28, 2016 (NASDAQ:IPXL) - September 28 at 5:29 PM logoImpax Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IPXL-US : September 27, 2016 (NASDAQ:IPXL) - September 27 at 10:16 AM logoImpax Launches Generic Version of Metadate CD® (Methylphenidate Hydrochloride Extended-Release Capsules) (NASDAQ:IPXL) - September 22 at 8:52 AM logoCommit To Buy Impax Laboratories At $22.50, Earn 15.8% Annualized Using Options (NASDAQ:IPXL) - September 14 at 5:46 PM
News IconBroker Outlook For The Week Ahead Impax Laboratories, Inc. (NASDAQ:IPXL) (NASDAQ:IPXL) - September 11 at 9:55 AM logoImpax to Present at the Morgan Stanley Global Healthcare Conference (NASDAQ:IPXL) - September 7 at 9:06 AM
News IconImpax Laboratories, Inc. Issues Voluntary, Nationwide Recall for One Lot of Lamotrig (NASDAQ:IPXL) - August 30 at 8:55 AM logoImpax Laboratories : Provides Update on Epinephrine Injection, USP Auto-Injector (NASDAQ:IPXL) - August 30 at 8:55 AM logoImpax Provides Update on Epinephrine Injection, USP Auto-Injector (NASDAQ:IPXL) - August 30 at 8:55 AM
News IconImpax Laboratories, Inc. Issues Voluntary, Nationwide Recall for One Lot of Lamotrigine Orally Disintegrating Tablet 200 mg ... (NASDAQ:IPXL) - August 27 at 5:13 PM logoImpax Laboratories, Inc. Issues Voluntary, Nationwide Recall for One Lot of Lamotrigine Orally Disintegrating … (NASDAQ:IPXL) - August 27 at 5:13 PM logo6:31 pm Impax Labs issues voluntary nationwide retail level recall for one lot of Lamotrigine Orally Disintegrating Tablet 200 mg (NASDAQ:IPXL) - August 27 at 10:09 AM logoImpax Laboratories, Inc. Issues Voluntary, Nationwide Recall for One Lot of Lamotrigine Orally Disintegrating Tablet 200 mg Due to the Potential for 100 mg Blister Cards being Packaged in 200 mg Containers (NASDAQ:IPXL) - August 27 at 10:09 AM logoETF’s with exposure to Impax Laboratories, Inc. : August 26, 2016 (NASDAQ:IPXL) - August 26 at 5:33 PM logoImpax Laboratories Stock Sees Short Interest Decline 42% (NASDAQ:IPXL) - August 25 at 5:42 PM logoWhy is there no generic EpiPen? (NASDAQ:IPXL) - August 25 at 5:42 PM
News IconRevenue Update on Impax Laboratories Inc(NASDAQ:IPXL) (NASDAQ:IPXL) - August 24 at 5:35 PM logoMylan: Five Reasons EpiPen Controversy Won't End Any Time Soon (NASDAQ:IPXL) - August 24 at 5:34 PM logoImpax Laboratories (IPXL) Adds New Board Member (NASDAQ:IPXL) - August 23 at 10:05 AM logoIMPAX LABORATORIES INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. (NASDAQ:IPXL) - August 22 at 5:45 PM
News IconImpax Laboratories Inc. (IPXL) PT Lowered to $30.00 (NASDAQ:IPXL) - August 22 at 10:15 AM logoRichard A. Bierly Appointed to Impax Laboratories Board of Directors (NASDAQ:IPXL) - August 22 at 10:15 AM logoAnalysts Set $29 Price Target For Impax Laboratories, Inc. (NASDAQ:IPXL) (NASDAQ:IPXL) - August 19 at 8:40 AM logoIMPAX LABORATORIES INC Financials (NASDAQ:IPXL) - August 18 at 5:43 PM logoETF’s with exposure to Impax Laboratories, Inc. : August 15, 2016 (NASDAQ:IPXL) - August 15 at 3:46 PM logoTop 6 Companies That Destroyed Shareholders Last Week (NASDAQ:IPXL) - August 14 at 10:16 AM logoImpax Laboratories, Inc. :IPXL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:IPXL) - August 12 at 5:47 PM logoThis "Cheap" Stock May Not Be a Bargain (NASDAQ:IPXL) - August 12 at 8:51 AM logoImpax Laboratories Has Returned 23.0% Since SmarTrend Recommendation (IPXL) (NASDAQ:IPXL) - August 11 at 5:55 PM logoImpax Laboratories Inc. (IPXL) Sank To A New Low After Weak Q2 Report (NASDAQ:IPXL) - August 11 at 8:46 AM logo52 Week New Lows Pre Market – EKSO, IPXL, IOTS, VRTU, NVGS, NXEO, CUI (NASDAQ:IPXL) - August 10 at 8:35 AM logoEdited Transcript of IPXL earnings conference call or presentation 9-Aug-16 12:30pm GMT (NASDAQ:IPXL) - August 10 at 8:35 AM logoImpax (IPXL) Stock Plummets on Weak Q2 Results, Guidance (NASDAQ:IPXL) - August 9 at 5:51 PM logoImpax Labs, Red Robin Burgers in Tuesday’s 52-Week Low Club (NASDAQ:IPXL) - August 9 at 5:51 PM logoMid-Afternoon Market Update: Endo Rises On Earnings Beat; Impax Laboratories Shares Slide (NASDAQ:IPXL) - August 9 at 3:28 PM logoImpax Labs reports 2Q loss (NASDAQ:IPXL) - August 9 at 8:41 AM logoImpax Reports Second Quarter 2016 Financial Results (NASDAQ:IPXL) - August 9 at 8:41 AM logoChanging Landscape for Generic-Drug Makers Creates Opportunities (NASDAQ:IPXL) - August 8 at 5:53 PM logo5 Stocks with Low Price-to-Cash-Flow Ratio to Buy Now (NASDAQ:IPXL) - August 8 at 10:24 AM logoETF’s with exposure to Impax Laboratories, Inc. : August 4, 2016 (NASDAQ:IPXL) - August 4 at 5:58 PM logoIMPAX LABORATORIES INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Creation of a Direct F (NASDAQ:IPXL) - August 3 at 6:00 PM logoImpax Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IPXL-US : August 2, 2016 (NASDAQ:IPXL) - August 2 at 5:56 PM logoShort Interest Expands By 12.8% For IPXL (NASDAQ:IPXL) - July 27 at 5:57 PM logo4 Low P/CF Stocks to Improve Your Value Investing (NASDAQ:IPXL) - July 22 at 7:43 AM


Impax Laboratories (NASDAQ:IPXL) Chart for Thursday, October, 27, 2016

Last Updated on 10/27/2016 by Staff